Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy.

MLA

Thompson, Jeffrey C., et al. “Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy.” JCO Precision Oncology, vol. 5, May 2021, pp. 510–24. EBSCOhost, https://doi.org/10.1200/PO.20.00321.

APA

Thompson, J. C., Carpenter, E. L., Silva, B. A., Rosenstein, J., Chien, A. L., Quinn, K., Espenschied, C. R., Mak, A., Kiedrowski, L. A., Lefterova, M., Nagy, R. J., Katz, S. I., Yee, S. S., Black, T. A., Singh, A. P., Ciunci, C. A., Bauml, J. M., Cohen, R. B., Langer, C. J., & Aggarwal, C. (2021). Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. JCO Precision Oncology, 5, 510–524. https://doi.org/10.1200/PO.20.00321

Chicago

Thompson, Jeffrey C., Erica L. Carpenter, Benjamin A. Silva, Jamie Rosenstein, Austin L. Chien, Katie Quinn, Carin R. Espenschied, et al. 2021. “Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy.” JCO Precision Oncology 5 (May): 510–24. doi:10.1200/PO.20.00321.